Introduction
Isocitrate dehydrogenase (IDH) is an enzyme family involved in cell
aerobic metabolism of tricarboxylic acid cycle, where IDH1 andIDH2 are commonly mutated metabolic genes in human cancers such
as glioma and hematologic malignancies [1,2]. Since a missense
mutation of IDH1 was first identified in progressive glioblastoma
in 2008 [3], numerous studies have been conducted to describe this
genetic mutation and to understand its biological impact on tumors
[4]. And it has been confirmed IDH1/2 mutations have been
associated with prognostic and predictive values as biomarkers [5].
The understanding of the role of IDH1/2 mutations in
tumorigenesis and early occurrence has led to the development ofIDH1/2 mutation inhibitors. IDH inhibitors have shown promising
efficacy not only in hematologic malignancies, but also in
cholangiocarcinoma patients harboring IDH1 mutations, such as
AG-120 (NCT02073994), AG-881 (NCT02481154) and BAY1436032 (NCT02746081)
[6-8]. However, the landscape of IDH1/2 mutations in
pan-cancer has not been fully characterized. In this study, we invested
the IDH1/2 pathologic or likely pathologic mutations landscape in
pan-cancer.